Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Gastrointestinal Neoplasms 1Ascites 1

Interventions

fludarabine 3aldesleukin 3Fluorouracil 3Cyclophosphamide 3Oxaliplatin 2Leucovorin 2Interleukin-2 2Gemcitabine 2sodium thiosulfate 1montanide ISA 51 1fludarabine phosphate 1detox adjuvant 1dehydroftorafur 1danvatirsen 1Tomography, X-Ray Computed 1Specimen Handling 1Positron-Emission Tomography 1Plicamycin 1Photography 1National Cancer Institute (U.S.) 1Mitomycin 1Microscopy, Electron 1Melphalan 1Magnetic Resonance Imaging 1MLN 8237 1Floxuridine 1Erlotinib Hydrochloride 1Electrocardiography 1Doxorubicin 1Diagnostic Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Gastrointestinal Neoplasms × danvatirsen × Clear all
NCT02417753 2017-05-15

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
1 enrolled 10 charts
GastrointestinalGynecologic

Ascites, Gastrointestinal Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡